세계의 DNA 마이크로어레이 시장 규모와 점유율 분석 : 유형별, 용도별, 최종사용자별 - 수요 예측(-2030년)

Market Overview

In 2023, the worldwide DNA microarray industry produced revenue of USD 1,982.1 million, which will attain USD 3,930.8 million by the end of the decade, growing at 10.5% CAGR during the projection period.

The development of this market can be explained by the increase in awareness and use of this technology in the detection process and IT world and, the evolution of software for it. DNA microarray has several applications ranging from agricultural biotechnology to disease diagnosis & monitoring, to protein expression & proteomics, and so on.

DNA microarrays are an ongoing advancement in the specially designed pathway for the very purpose of - diagnosis and prognosis, targeted therapies, and many other conditions. First of all, the treatment methods of the diseases through the traditional way they cannot make the precise diagnosis and treat the disease. Because of that, personalized medicine has come to be considered.

These diseases comprising of cancer and immune disorders are the most threatening of the bunch which bring great implications on each person's prognosis and treatment by considering the acquisition of full genome understanding. Thus, along with this rise in the number of individuals who are in favor of tailored medicine, we can see the expansion of the industry.

The DNA microarray is a crucial component that is everywhere in genome mapping and sequencing processes. However, despite of this quite recent observation, the application of these microarray studies rose in diagnostics and detection of diseases of infectious origin, genetic basis of diseases, cancer diagnostics, new drugs research, pharmacogenomics, etc.

Key Insights

The oligonucleotide DNA microarray category held the largest share, 70%, and is estimated to uphold supremacy because of cost-efficiency and accurate gene expression monitoring abilities.

It has the potential to screen hybridization specificity and therefore is regarded as a key technique for researching single nucleotide polymorphisms (SNPs).

The cDNA microarray segment is projected to record the highest CAGR, given the vital applications of this technology in studying gene expression across several species.

In 2023, the pharmaceutical & biotechnology industry held the largest share, of more than 40%, and the category is also projected to remain dominant because of augmented acceptance of DNA microarrays in drug discovery and research.

Development in research activities for finding new drug molecules supports industry growth in this category.

DNA microarrays are attaining significance in cancer research, classifying molecular markers with diagnostic potential for numerous human cancers.

Hospitals & diagnostic centers will witness the fastest development, propelled by the acceptance of DNA microarray tech in clinical diagnostics.

Advanced laboratories utilize DNA microarrays for detecting numerous polymorphisms in a single assay using biochips.

In 2023, the North American region had a significant share, around 40%, and is forecasted to advance at a strong CAGR.

Major reasons propelling this development include the existence of key industry players investing in technically enhanced DNA microarray items.

The continent witnessed a surge in difficult-to-diagnose and treat diseases, leading to augmented demand for microarrays.

Canada's market is growing rapidly with the boom of superior healthcare infrastructure, government support systems initiating perfect diabetes, and the surge of chronic diseases.

Revenue dynamics in the healthcare sector, in particular biotechnology, are largely influenced by innovative investments in North America.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by type
  • 1.4.2. Market size breakdown, by application
  • 1.4.3. Market size breakdown, by end user
  • 1.4.4. Market size breakdown, by region
  • 1.4.5. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Market Indicators

Chapter 6. Industry Outlook

• 6.1. Market Dynamics
  • 6.1.1. Trends
  • 6.1.2. Drivers
  • 6.1.3. Restraints/challenges
  • 6.1.4. Impact analysis of drivers/restraints
• 6.2. Impact of COVID-19
• 6.3. Porter's Five Forces Analysis
  • 6.3.1. Bargaining power of buyers
  • 6.3.2. Bargaining power of suppliers
  • 6.3.3. Threat of new entrants
  • 6.3.4. Intensity of rivalry
  • 6.3.5. Threat of substitutes
• 6.4. Technology Analysis
• 6.5. Regulatory Framework

Chapter 7. Competitive Landscape

• 7.1. List of Market Players and their Offerings
• 7.2. Competitive Benchmarking of Key Players
• 7.3. Product Benchmarking of Key Players
• 7.4. Recent Strategic Developments

Chapter 8. Global Market

• 8.1. Overview
• 8.2. Market Revenue, by Type (2017-2030)
• 8.3. Market Revenue, by Application (2017-2030)
• 8.4. Market Revenue, by End User (2017-2030)
• 8.5. Market Revenue, by Region (2017-2030)

Chapter 9. North America Market

• 9.1. Overview
• 9.2. Market Revenue, by Type (2017-2030)
• 9.3. Market Revenue, by Application (2017-2030)
• 9.4. Market Revenue, by End User (2017-2030)
• 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. Europe Market

• 10.1. Overview
• 10.2. Market Revenue, by Type (2017-2030)
• 10.3. Market Revenue, by Application (2017-2030)
• 10.4. Market Revenue, by End User (2017-2030)
• 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. APAC Market

• 11.1. Overview
• 11.2. Market Revenue, by Type (2017-2030)
• 11.3. Market Revenue, by Application (2017-2030)
• 11.4. Market Revenue, by End User (2017-2030)
• 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. LATAM Market

• 12.1. Overview
• 12.2. Market Revenue, by Type (2017-2030)
• 12.3. Market Revenue, by Application (2017-2030)
• 12.4. Market Revenue, by End User (2017-2030)
• 12.5. Market Revenue, by Country (2017-2030)

Chapter 13. MEA Market

• 13.1. Overview
• 13.2. Market Revenue, by Type (2017-2030)
• 13.3. Market Revenue, by Application (2017-2030)
• 13.4. Market Revenue, by End User (2017-2030)
• 13.5. Market Revenue, by Country (2017-2030)

Chapter 14. U.S. Market

• 14.1. Overview
• 14.2. Market Revenue, by Type (2017-2030)
• 14.3. Market Revenue, by Application (2017-2030)
• 14.4. Market Revenue, by End User (2017-2030)

Chapter 15. Canada Market

• 15.1. Overview
• 15.2. Market Revenue, by Type (2017-2030)
• 15.3. Market Revenue, by Application (2017-2030)
• 15.4. Market Revenue, by End User (2017-2030)

Chapter 16. Germany Market

• 16.1. Overview
• 16.2. Market Revenue, by Type (2017-2030)
• 16.3. Market Revenue, by Application (2017-2030)
• 16.4. Market Revenue, by End User (2017-2030)

Chapter 17. France Market

• 17.1. Overview
• 17.2. Market Revenue, by Type (2017-2030)
• 17.3. Market Revenue, by Application (2017-2030)
• 17.4. Market Revenue, by End User (2017-2030)

Chapter 18. U.K. Market

• 18.1. Overview
• 18.2. Market Revenue, by Type (2017-2030)
• 18.3. Market Revenue, by Application (2017-2030)
• 18.4. Market Revenue, by End User (2017-2030)

Chapter 19. Italy Market

• 19.1. Overview
• 19.2. Market Revenue, by Type (2017-2030)
• 19.3. Market Revenue, by Application (2017-2030)
• 19.4. Market Revenue, by End User (2017-2030)

Chapter 20. Spain Market

• 20.1. Overview
• 20.2. Market Revenue, by Type (2017-2030)
• 20.3. Market Revenue, by Application (2017-2030)
• 20.4. Market Revenue, by End User (2017-2030)

Chapter 21. China Market

• 21.1. Overview
• 21.2. Market Revenue, by Type (2017-2030)
• 21.3. Market Revenue, by Application (2017-2030)
• 21.4. Market Revenue, by End User (2017-2030)

Chapter 22. Japan Market

• 22.1. Overview
• 22.2. Market Revenue, by Type (2017-2030)
• 22.3. Market Revenue, by Application (2017-2030)
• 22.4. Market Revenue, by End User (2017-2030)

Chapter 23. India Market

• 23.1. Overview
• 23.2. Market Revenue, by Type (2017-2030)
• 23.3. Market Revenue, by Application (2017-2030)
• 23.4. Market Revenue, by End User (2017-2030)

Chapter 24. South Korea Market

• 24.1. Overview
• 24.2. Market Revenue, by Type (2017-2030)
• 24.3. Market Revenue, by Application (2017-2030)
• 24.4. Market Revenue, by End User (2017-2030)

Chapter 25. Australia Market

• 25.1. Overview
• 25.2. Market Revenue, by Type (2017-2030)
• 25.3. Market Revenue, by Application (2017-2030)
• 25.4. Market Revenue, by End User (2017-2030)

Chapter 26. Brazil Market

• 26.1. Overview
• 26.2. Market Revenue, by Type (2017-2030)
• 26.3. Market Revenue, by Application (2017-2030)
• 26.4. Market Revenue, by End User (2017-2030)

Chapter 27. Mexico Market

• 27.1. Overview
• 27.2. Market Revenue, by Type (2017-2030)
• 27.3. Market Revenue, by Application (2017-2030)
• 27.4. Market Revenue, by End User (2017-2030)

Chapter 28. Saudi Arabia Market

• 28.1. Overview
• 28.2. Market Revenue, by Type (2017-2030)
• 28.3. Market Revenue, by Application (2017-2030)
• 28.4. Market Revenue, by End User (2017-2030)

Chapter 29. South Africa Market

• 29.1. Overview
• 29.2. Market Revenue, by Type (2017-2030)
• 29.3. Market Revenue, by Application (2017-2030)
• 29.4. Market Revenue, by End User (2017-2030)

Chapter 30. U.A.E. Market

• 30.1. Overview
• 30.2. Market Revenue, by Type (2017-2030)
• 30.3. Market Revenue, by Application (2017-2030)
• 30.4. Market Revenue, by End User (2017-2030)

Chapter 31. Company Profiles

• 31.1. Thermo Fisher Scientific Inc.
  • 31.1.1. Business overview
  • 31.1.2. Product and service offerings
  • 31.1.3. Key financial summary
• 31.2. Agilent Technologies Inc.
  • 31.2.1. Business overview
  • 31.2.2. Product and service offerings
  • 31.2.3. Key financial summary
• 31.3. Illumina Inc.
  • 31.3.1. Business overview
  • 31.3.2. Product and service offerings
  • 31.3.3. Key financial summary
• 31.4. F. Hoffmann-La Roche Ltd.
  • 31.4.1. Business overview
  • 31.4.2. Product and service offerings
  • 31.4.3. Key financial summary
• 31.5. QIAGEN N.V.
  • 31.5.1. Business overview
  • 31.5.2. Product and service offerings
  • 31.5.3. Key financial summary
• 31.6. Merck KGaA
  • 31.6.1. Business overview
  • 31.6.2. Product and service offerings
  • 31.6.3. Key financial summary
• 31.7. PerkinElmer Inc.
  • 31.7.1. Business overview
  • 31.7.2. Product and service offerings
  • 31.7.3. Key financial summary
• 31.8. Applied Microarrays LLC
  • 31.8.1. Business overview
  • 31.8.2. Product and service offerings
  • 31.8.3. Key financial summary
• 31.9. Savyon Diagnostics
  • 31.9.1. Business overview
  • 31.9.2. Product and service offerings
  • 31.9.3. Key financial summary

Chapter 32. Appendix

• 32.1. Abbreviations
• 32.2. Sources and References
• 32.3. Related Reports